{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:32:48Z","timestamp":1787239968149,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroimaging Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.nic.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:34:39Z","timestamp":1779190479000},"page":"545-560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-Treatment Causes of Encephalopathy"],"prefix":"10.1016","volume":"36","author":[{"given":"Rami W.","family":"Eldaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nic.2026.02.003_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJM200108093450606","article-title":"Toxic leukoencephalopathy","volume":"345","author":"Filley","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nic.2026.02.003_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3174\/ajnr.A5947","article-title":"Acute toxic leukoencephalopathy: etiologies, imaging findings, and outcomes in 101 patients","volume":"40","author":"\u00d6z\u00fctemiz","year":"2019","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.nic.2026.02.003_bib3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2214\/AJR.08.1176","article-title":"Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging","volume":"193","author":"McKinney","year":"2009","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"10.1016\/j.nic.2026.02.003_bib4","first-page":"1328","article-title":"Potentially reversible and recognizable acute encephalopathic syndromes: disease categorization and MRI appearances","volume":"41","author":"Koksel","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"10.1016\/j.nic.2026.02.003_bib5","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1148\/rg.2019190016","article-title":"Imaging patterns of toxic and metabolic brain disorders","volume":"39","author":"de Oliveira","year":"2019","journal-title":"Radiographics"},{"issue":"Suppl 5","key":"10.1016\/j.nic.2026.02.003_bib6","first-page":"v108","article-title":"A review of neurotoxicities associated with immunotherapy and a framework for evaluation","volume":"3","author":"Burton","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1067\/j.cpradiol.2023.06.016","article-title":"Good gone bad: complications of chemotherapy, immunotherapy, and radiotherapy on the CNS","volume":"53","author":"Mallikarjun","year":"2024","journal-title":"Curr Probl Diagn Radiol"},{"issue":"3","key":"10.1016\/j.nic.2026.02.003_bib8","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.25.33139","article-title":"Role of neuroimaging in cancer-treatment neurotoxicity","volume":"225","author":"Hassankhani","year":"2025","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.6004\/jnccn.2016.0007","article-title":"Prevalence and safety of off-label use of chemotherapeutic agents in older patients with breast cancer: estimates from SEER-medicare data","volume":"14","author":"Eaton","year":"2016","journal-title":"J Natl Compr Cancer Netw"},{"issue":"2","key":"10.1016\/j.nic.2026.02.003_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","article-title":"Cancer-treatment-induced neurotoxicity--focus on newer treatments","volume":"13","author":"Stone","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nic.2026.02.003_bib11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.nic.2026.02.003_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015691","article-title":"Chemotherapy-induced posterior reversible encephalopathy syndrome: three case reports","volume":"98","author":"Cacho-D\u00edaz","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"8","key":"10.1016\/j.nic.2026.02.003_bib13","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00415-016-8377-8","article-title":"Posterior reversible encephalopathy syndrome","volume":"264","author":"Fischer","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.nic.2026.02.003_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2019.07.018","article-title":"Posterior reversible encephalopathy syndrome: a review with emphasis on neuroimaging characteristics","volume":"404","author":"Tetsuka","year":"2019","journal-title":"J Neurol Sci"},{"issue":"7","key":"10.1016\/j.nic.2026.02.003_bib15","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3174\/ajnr.A0549","article-title":"Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome","volume":"28","author":"Bartynski","year":"2007","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1016\/j.nic.2026.02.003_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16246","article-title":"Frequency of ischemic stroke and intracranial haemorrhage in patients with reversible cerebral vasoconstriction syndrome (RCVS) and posterior reversible encephalopathy syndrome (PRES) - a systematic review","volume":"31","author":"Kaufmann","year":"2024","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.1016\/j.nic.2026.02.003_bib17","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.3390\/ijms21103483","article-title":"Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers","volume":"21","author":"Ko\u017ami\u0144ski","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.nic.2026.02.003_bib18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2013.53.0808","article-title":"Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia","volume":"32","author":"Bhojwani","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.nic.2026.02.003_bib19","first-page":"1263","article-title":"Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate","volume":"26","author":"Reddick","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"10.1016\/j.nic.2026.02.003_bib20","first-page":"836","article-title":"Widening spectrum of a reversible splenial lesion with transiently reduced diffusion","volume":"27","author":"Takanashi","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"issue":"7","key":"10.1016\/j.nic.2026.02.003_bib21","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1007\/s00330-023-10524-3","article-title":"Cytotoxic lesions of the corpus callosum: a systematic review","volume":"34","author":"Moors","year":"2024","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.nic.2026.02.003_bib22","first-page":"1983","article-title":"Transient splenial lesion of the corpus callosum in clinically mild influenza-associated encephalitis\/encephalopathy","volume":"27","author":"Bulakbasi","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.nic.2026.02.003_bib23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jon.12455","article-title":"Lesions in the splenium of the corpus callosum on MRI in children: a review","volume":"27","author":"Kontzialis","year":"2017","journal-title":"J Neuroimaging"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13244-023-01602-7","article-title":"MRI characteristics of chemotherapy-related central neurotoxicity: a pictorial review","volume":"15","author":"Isaac","year":"2024","journal-title":"Insights Imaging"},{"issue":"9","key":"10.1016\/j.nic.2026.02.003_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11910-016-0686-x","article-title":"Chemotherapy-related neurotoxicity","volume":"16","author":"Taillibert","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"10.1016\/j.nic.2026.02.003_bib26","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4103\/0973-1482.168993","article-title":"A rare case of chemotherapy induced reversible cerebral vasoconstriction syndrome in a patient of acute lymphocytic leukemia","volume":"11","author":"Sankhe","year":"2015","journal-title":"J Cancer Res Therapeut"},{"issue":"25","key":"10.1016\/j.nic.2026.02.003_bib27","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.nic.2026.02.003_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00234-017-1809-z","article-title":"Potentially reversible acute cerebellar toxicity associated with minnelide","volume":"59","author":"Khanipour Roshan","year":"2017","journal-title":"Neuroradiology"},{"issue":"7","key":"10.1016\/j.nic.2026.02.003_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae186","article-title":"Immune-related encephalitis after immune checkpoint inhibitor therapy","volume":"30","author":"Buckley","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.nic.2026.02.003_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2022.08.009","article-title":"Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study","volume":"175","author":"M\u00fcller-Jensen","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nic.2026.02.003_bib32","article-title":"Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study","volume":"44","author":"Farina","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"10.1016\/j.nic.2026.02.003_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11060-022-03997-7","article-title":"Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review","volume":"157","author":"Nannini","year":"2022","journal-title":"J Neuro Oncol"},{"issue":"10","key":"10.1016\/j.nic.2026.02.003_bib34","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1007\/s00415-024-12660-2","article-title":"Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients","volume":"271","author":"Pichon","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.nic.2026.02.003_bib35","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.nic.2026.02.003_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.538695","article-title":"Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature","volume":"11","author":"Oliveira","year":"2020","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.nic.2026.02.003_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.nic.2026.02.003_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.nic.2026.02.003_bib39","first-page":"1683","article-title":"MRI findings of immune checkpoint inhibitor-induced hypophysitis: possible association with fibrosis","volume":"41","author":"Kurokawa","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"issue":"26","key":"10.1016\/j.nic.2026.02.003_bib40","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nic.2026.02.003_bib41","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3389\/fimmu.2018.02740","article-title":"CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success","volume":"9","author":"Long","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib42","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.4110\/in.2022.22.e6","article-title":"CAR T cell immunotherapy beyond haematological malignancy","volume":"22","author":"Hupperetz","year":"2022","journal-title":"Immune Netw"},{"issue":"5","key":"10.1016\/j.nic.2026.02.003_bib43","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.nic.2026.02.003_bib45","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.nic.2026.02.003_bib46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nic.2026.02.003_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"ImmunoTargets Ther"},{"issue":"6","key":"10.1016\/j.nic.2026.02.003_bib49","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2214\/AJR.21.26091","article-title":"CAR T-Cell therapy: an update for radiologists","volume":"217","author":"Yoon","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"10.1016\/j.nic.2026.02.003_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005459","article-title":"Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy","volume":"10","author":"Amidi","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.nic.2026.02.003_bib51","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.nic.2026.02.003_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.medin.2020.06.014","article-title":"Immune effector cell-associated neurotoxicity syndrome: a therapeutic approach in the critically ill","volume":"46","author":"Suarez Montero","year":"2022","journal-title":"Med Intensiva"},{"issue":"7","key":"10.1016\/j.nic.2026.02.003_bib53","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214086","article-title":"Neuroimaging findings in children and young adults with neurotoxicity after CAR T-Cell therapy for B-Cell malignancies","volume":"105","author":"McGuire","year":"2025","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.nic.2026.02.003_bib54","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.nic.2026.02.003_bib55","first-page":"E50","article-title":"Chimeric antigen receptor T-Cell neurotoxicity neuroimaging: more than meets the eye","volume":"40","author":"Gust","year":"2019","journal-title":"AJNR Am J Neuroradiol"},{"issue":"Suppl 1","key":"10.1016\/j.nic.2026.02.003_bib56","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/647939","article-title":"Metronidazole is still the drug of choice for treatment of anaerobic infections","volume":"50","author":"L\u00f6fmark","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.nic.2026.02.003_bib57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2165\/00003495-199754050-00003","article-title":"Metronidazole. A therapeutic review and update","volume":"54","author":"Freeman","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.nic.2026.02.003_bib58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7326\/0003-4819-101-1-92","article-title":"The neurotoxicity of antibacterial agents","volume":"101","author":"Snavely","year":"1984","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.nic.2026.02.003_bib59","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3174\/ajnr.A0655","article-title":"MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings","volume":"28","author":"Kim","year":"2007","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"10.1016\/j.nic.2026.02.003_bib60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/WNF.0b013e3182334b35","article-title":"Metronidazole-induced central nervous system toxicity: a systematic review","volume":"34","author":"Kuriyama","year":"2011","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"10.1016\/j.nic.2026.02.003_bib61","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.nic.2026.02.003_bib62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1971400915598082","article-title":"Vigabatrin-induced MRI changes associated with extrapyramidal symptoms in a child with infantile spasms","volume":"28","author":"Schonstedt","year":"2015","journal-title":"NeuroRadiol J"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib63","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/epi4.13099","article-title":"Symptomatic vigabatrin-associated MRI toxicity is associated with simultaneous hormonal therapy among patients with infantile spasms","volume":"10","author":"Sathe","year":"2025","journal-title":"Epilepsia Open"},{"issue":"7","key":"10.1016\/j.nic.2026.02.003_bib64","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1528-1167.2010.02564.x","article-title":"Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms","volume":"51","author":"Dracopoulos","year":"2010","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.nic.2026.02.003_bib65","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/dmcn.12188","article-title":"An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms","volume":"55","author":"Fong","year":"2013","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"10.1016\/j.nic.2026.02.003_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16049","article-title":"Anti-amyloid antibody treatments for alzheimer\u2019s disease","volume":"31","author":"Perneczky","year":"2024","journal-title":"Eur J Neurol"},{"issue":"11","key":"10.1016\/j.nic.2026.02.003_bib67","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3174\/ajnr.A8469","article-title":"Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities","volume":"46","author":"Cogswell","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"10.1016\/j.nic.2026.02.003_bib69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.nic.2026.02.003_bib70","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.nic.2026.02.003_bib71","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3174\/ajnr.A3500","article-title":"MR imaging features of amyloid-related imaging abnormalities","volume":"34","author":"Barakos","year":"2013","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Neuroimaging Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052514926000067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052514926000067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:13:55Z","timestamp":1787238835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052514926000067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1052514926000067"],"URL":"https:\/\/doi.org\/10.1016\/j.nic.2026.02.003","relation":{},"ISSN":["1052-5149"],"issn-type":[{"value":"1052-5149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-Treatment Causes of Encephalopathy","name":"articletitle","label":"Article Title"},{"value":"Neuroimaging Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nic.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}